SPOTLIGHT: Speedel halts trial

Shares of Switzerland's Speedel were hit hard by yesterday's announcement that the company was halting a trial of its diabetes therapy Avosentan after patients receiving the drug experienced excessive fluid retention. Speedel CEO Alice Huxley said that the company may change the design of the trial to eliminate the side effect. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.